gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · VTRSHealthcarePharmaceuticals

Viatris Inc. Common Stock (VTRS)

$19.22+1.59%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$19.22▲ 83.22% in range
Nov 4, 2025Low $10.11 · High $19.22Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Viatris closed at $19.22 on Nov 4, up 1.59% — matching its 52-week closing high. Volume of 8.5M shares was 0.97× its 20-day average (close to normal).

Split-adjusted performance: +9.6% over one month, +20.5% over six months, +82.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $3.76B, up 4.9% from a year earlier, with a net margin of -3.2%.

Short interest was 37.9M shares at the Oct 15 settlement, down 9.8% from the prior report (3.3% of float, 4.6 days to cover).

Market cap$22.08B1.15B shares
Revenue · quarter$3.76B+4.9% YoY
Diluted EPS$-0.10—
P/E · TTM—P/S 1.5×
Net margin-3.2%Gross 38.8%
Dividend yield2.50%$0.12 last paid
52-week range10.11 – 19.220.0% from high
Volume8.5M0.97× 20-day avg
Volatility · 60d23.4%Annualised
Short % of float3.3%4.6 days to cover
Net cash-$12.46BCash $886.5M
Next earnings—Not scheduled
Split-adjusted performance
1W +2.4%1M +9.6%3M +18.0%6M +20.5%YTD +54.4%1Y +82.5%3Y +117.4%5Y +46.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum82
Revenue growth47
Net margin67
Value (low P/E)—
Size96

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short37.9M−9.8% vs prior
Days to cover4.6Settled Oct 15
% of float3.3%
Short vol. 10d51.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
VTRSViatris$19.22+1.59%+20.5%+4.9%−3.2%—$22.08B
ALNYAlnylam Pharmaceuticals$161.08+0.74%−46.8%+16.7%148.6%7.9$21.57BCompare
INSMInsmed$110.00+5.32%−19.8%+268.4%−19.1%—$24.13BCompare
UTHRUnited Therapeutics$608.49+1.19%+2.0%−1.9%42.5%19.9$26.10BCompare
ROIVRoivant Sciences$38.23+6.08%+32.7%−33.5%−13164.8%—$27.61BCompare
RPRXRoyalty Pharma$67.56+1.75%+33.2%+16.5%2.7%36.9$30.08BCompare
JAZZJazz Pharmaceuticals$234.66+2.14%+2.7%+10.4%−38.9%74.0$15.23BCompare
BBIOBridgeBio Pharma$77.89+5.21%+14.4%+192.6%−23.5%—$15.17BCompare
ZTSZOETIS$89.20+7.48%−19.8%−0.2%28.0%14.1$36.86BCompare

News about Viatris

All news →
Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Zacks Investment Research · 1d ago▲ PositiveWill Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research · Oct 27, 2026▲ PositiveWhy Viatris (VTRS) is a Top Momentum Stock for the Long-TermZacks Investment Research · Oct 26, 2026▲ PositiveViatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioZacks Investment Research · Oct 9, 2026▲ PositiveVTRS vs. AVTR: Which Stock Is the Better Value Option?Zacks Investment Research · Oct 6, 2026▲ Positive

Quick answers

What does Viatris do?
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries.
What is VTRS's market cap?
$22.08B, based on the Nov 4 close of $19.22.
Does Viatris pay a dividend?
Yes. The latest regular dividend was $0.12 per share (ex-date Aug 21), an annualised yield of 2.50%.
How much of VTRS is sold short?
37.9M shares, 3.3% of float, as of Oct 15, 2026.
What sector is VTRS in?
Healthcare, in the Pharmaceuticals industry.

About Viatris

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.

HQ: Canonsburg, PA30,000 employeesListed Feb 23, 1973viatris.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology